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ABSTRACT
Objectives: Although there has recently been substantial
interest in a Medicare drug beneﬁt program, little atten-
tion has focused on ensuring improved access to medica-
tion monitoring for Medicare beneﬁciaries. Using a
societal perspective, we evaluated the impact pharmacists
could have on inappropriate prescribing, patient compli-
ance, and medication-related morbidity and mortality
within a Medicare drug beneﬁts program.
Methods: A cost-effectiveness analysis from a societal
perspective was performed. A comprehensive MEDLINE
search for relevant literature identiﬁed data sources and
model parameters.
Results: In the base case, a pharmaceutical care beneﬁt
in the elderly population would cost $2100 (year 2000
prices) per life-year saved, which is highly cost-effective.
Reasonable changes in model parameters did not raise
the cost-effectiveness ratio above $13,000 per life-year
saved.
Conclusion: Despite limitations in both the quantity and
the speciﬁcity of data available, pharmaceutical care
appears to be a highly cost-effective augmentation to a
Medicare drug beneﬁt program. This result is robust to
model parameter changes. This model is conservative in
that it does not include ongoing beneﬁts from medication
monitoring or increased elderly drug utilization and poly-
pharmacy as the Medicare drug program is phased in.
Keywords: cost-effectiveness analysis, drug utilization,
gerontology, Medicare, pharmaceutical care.
Introduction
The cost of medication-related morbidity and mor-
tality has received increasing attention in recent
years [1–4]. As the number and complexity of pre-
scriptions ﬁlled each year increases, the cost associ-
ated with medication misuse also increases [2,3].
Adding to the increased interest is the recently
released Institute of Medicine (IOM) report (2000),
To Err is Human, and Congress’ consideration of
adding a comprehensive prescription drug beneﬁt to
Medicare, the primary health-care payer for elderly
and disabled Americans [6].
Medicare PART B (nonhospital beneﬁts) cur-
rently offers only limited coverage of outpatient
medications. Since 1999, there has been renewed
interest in expanding Medicare coverage to include
outpatient prescription medications because of the
increasing burden that the cost of medications has
placed on the elderly. In that year, the National
Academy of Social Insurance estimated that the
average Medicare enrollee spent $942 on prescrip-
tion medications [7].
This is not the ﬁrst attempt to expand Medicare
coverage to include prescription drugs. The Medi-
care Catastrophic Coverage Act of 1988 offered
catastrophic prescription drug coverage, but was
repealed in 1989. The proposed 1994 Health Secu-
rity Act would have added a prescription beneﬁt to
Medicare part B. The cost of implementing a drug
beneﬁt is controversial, and dependent on program
design. Recent estimates of adding a comprehensive
drug beneﬁt to the Medicare program are upwards
of $30 billion annually [8]. To our knowledge, none
of the proposals circulated on Capitol Hill during
the 107th congress include explicit reimbursement
for medication misuse monitoring and drug infor-
mation counseling to augment the drug beneﬁt
program.
The direct cost of medication-misuse-related
events, including additional physician visits, hospi-
tal admissions, emergency department visits, long-
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term-care facility admissions, and additional pre-
scriptions, has been estimated at $177.4 billion (in
year 2000 US$) [2]. Costs to a managed care plan
for elderly patients taking a potentially inappropri-
ate medication were more than double that of
patients not receiving such medication during a 6-
month time period [9]. In addition to the direct
costs, it has been estimated that 106,000 patients
die in hospitals [10] and a total of 218,113 people
die each year because of medication-related adverse
events [2].
The IOM (2000) report deﬁnes error as “the fail-
ure of a planned action to be completed as intended
or the use of a wrong plan to achieve an aim” [5].
Regarding the use of medication, this includes not
only administration errors (delivering the wrong
drug to the wrong patient), but also errors in diag-
nosis and prescribing on the part of the provider
and compliance on the part of the patient.
Medication-related errors as deﬁned by the IOM
are especially of concern in the elderly population.
In 1995, Medicare beneﬁciaries on average spent
more than four times as much as the nonelderly
population on prescriptions [6]. In addition, the eld-
erly may be especially susceptible to adverse medi-
cation events as a result of multiple concurrent
chronic diseases and decreased physiologic ability
to eliminate or metabolize medications [11]. With
nearly 3 billion prescriptions ﬁlled in the United
States in 2000 [12,13], the need for medication
management has become apparent [14].
The changing role of pharmacy in monitoring
medication usage is subsumed under the term “phar-
maceutical care.” Hepler and Strand [15] deﬁned
“pharmaceutical care” as “. . . responsible provi-
sion of drug therapy for the purpose of achieving
deﬁnite outcomes that improve a patient’s quality of
life.” Pharmacists have been shown to decrease pre-
scribing errors in an intensive care unit by 66% by
participating in physician rounds [16]. Patients
monitored by pharmacists in a skilled nursing facil-
ity in Los Angeles had signiﬁcantly fewer deaths and
greater discharges to lower levels of care compared
with patients not receiving this service [17]. Phar-
macists working in nursing homes have been pro-
jected to improve optimal therapeutic outcomes by
18% and to save $3.6 billion annually in costs from
avoided medication-related problems [18].
In a community pharmacy setting, pharmacists
are able to provide a variety of pharmaceutical care
services. This includes reviewing prescriptions for
appropriateness for each individual patient accord-
ing to the patient’s age, other medical conditions,
concurrent medications, and other relevant factors.
Pharmacists are also able to track reﬁll patterns and
counsel patients, when necessary, on the importance
of compliance with their medication regimen. Addi-
tionally, pharmacists are in the position to monitor
a medication’s effectiveness by performing blood
pressure readings, cholesterol checks, blood glucose
checks, etc., and to detect potential side effects by
discussing with the patient any concerns that he or
she might have.
Pharmacists are in a unique position to affect
medication-related morbidity and mortality in the
ambulatory setting. Pharmacists have substantial
contact with patients as most are seen monthly
for prescription reﬁlls. Also, pharmacists provide
the ﬁnal review of a prescription before a patient
receives a new medication, often have greatest
knowledge of all the prescription medications a
patient is taking, and can screen for drug interac-
tions and other potential problems.
Although pharmacists are in an optimal position
to provide pharmaceutical care, currently feasible
opportunities are limited. Pharmacies are reim-
bursed only for dispensing prescriptions and not for
providing medication management services. This
focus on ﬁlling prescriptions often does not allow
time to fully review a patient’s medication history
and reﬁll patterns and to counsel the patient on the
importance of compliance and potential side effects
[19]. Additionally, if a pharmacist reviews a pre-
scription and considers it potentially inappropriate
and the consultation with the prescriber results in
the discontinuation of that prescription, the phar-
macist receives no compensation for the service pro-
vided and has also lost the reimbursement for the
dispensing of that medication.
Public ofﬁcials have recently recognized the
potential beneﬁcial impact of pharmacists on med-
ication therapy. In May 2001, Senator Tim Johnson
of South Dakota introduced legislation that would
expand the Social Security Act to provide for cov-
erage of pharmacist services under part B of the
Medicare program (Senate Bill S.294). To our
knowledge, there has been no analysis to date of the
cost-effectiveness of a comprehensive plan to pro-
vide pharmaceutical care in the ambulatory setting
to elderly Americans. Such an analysis would pro-
vide decision makers with beneﬁcial information for
the evaluation of any proposed Medicare drug ben-
eﬁt plan.
Objectives
The purpose of this study was to evaluate the effect
that community pharmacists could have on medica-
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tion-related morbidity and mortality in the elderly
population in the United States if a comprehensive
pharmaceutical care intervention were included in
a Medicare drug beneﬁt program. The objectives
were to quantify from society’s perspective the cost-
effectiveness of the impact pharmacists could have
on inappropriate prescribing and patient compli-
ance and the subsequent impact on medication-
related hospitalizations, emergency room visits,
nursing home admissions, and mortality.
Methods
Cost-Effectiveness Methods
The cost-effectiveness model was constructed from
a societal perspective; however, we were not able to
include indirect costs because of lack of data. All
costs and beneﬁts were estimated for the remaining
lifetime of all elderly persons in the United States in
the year 2000, in which all costs and beneﬁts
recurred annually until death. All cost estimates
were inﬂated to year 2000 dollars using the medical
care  component  of  the  Consumer  Price  Index
(http://www.bls.gov/oes/1999/oes2910591.htm,
accessed June 19, 2001). The base case discount
rate for costs and beneﬁts was 3% [20].
Data Collection and Selection
Model parameters were derived through review of
the literature. Base case parameter values were
taken as the medians from ranges identiﬁed in
included studies. Studies were identiﬁed by search-
ing for the following key words in MEDLINE: med-
ication errors, prescription drugs, adverse effects,
economics, statistics and numerical data, mortality,
pharmaceutical services, pharmacists, drug therapy,
and community pharmacy services. From these arti-
cles, additional literature was identiﬁed from the
references cited. In general, sources were excluded if
conducted outside of the United States [21–23].
Studies reviewed from the literature did not receive
differential weights based on a quality adjustment.
Instead, a full range of parameter estimates reported
in the literature was incorporated into model sensi-
tivity analysis.
Base case model equations are presented in
Table 1 and parameters are presented in Tables 2
and 3. Calculated parameters related to the impact
of medication-related morbidity and mortality and
pharmaceutical care are given in Table 2. The
remaining base case parameters are shown in
Table 3.
Costs of Medication-Related Morbidity and Mortality
Hospitalizations. Published sources were used to
estimate the percentage of hospitalizations per year
that are medication-related. This estimate was then
combined with the percentage of hospitalizations
that are elderly to calculate the number of hospital-
izations per year that occur in the elderly because of
medication-related adverse events (Table 1).
The base case percent of medication-related hos-
pitalizations (5.1%) is the median of several pub-
lished sources (Table 2) [2,24–27]. Studies were
excluded if they reported the medication-related
admits as a percentage of the emergency admissions
rather than as a percentage of the total admissions
[28].
The percentage of medication-related hospitali-
zations resulting from inappropriate prescribing
(48.6%) and compliance (31.6%) is based on pub-
Table 1 Calculation of model parameters
Parameter Equation
Hospitalizations that are medication-related Total number of hospitalizations in the United States per year ¥ percentage of hospitalized
patients who are elderly ¥ percentage of hospitalizations that are medication-related ¥
average cost of a hospitalization
ED visits that are medication-related Total number of ED visits made by the elderly per year ¥ percentage of ED visits that are
medication-related ¥ the average cost of an ED visit
Ofﬁce visits that are medication-related Total number of medication-related ofﬁce visits per year ¥ percentage of ofﬁce visits that
are used by the elderly
NH admissions that are medication-related Total number of NH admissions per year ¥ percentage of NH residents that are elderly ¥
percentage of NH admissions that are medication-related ¥ 6 months ¥ average monthly
cost of NH care
Cost of providing pharmaceutical care (P(not dying from any cause during the year) ¥ cost of pharmaceutical care for the ﬁrst 
year) + (P(not dying from any cause during the year) ¥ cost of pharmaceutical care in 
subsequent years) + (P(dying from any cause) ¥ the cost of pharmaceutical care in subsequent
years)
Discounted life expectancy at every age P(not dying from any cause during this year) + P(not dying from any cause) ¥ discounted life
expectancy from the subsequent year + P(dying from any cause this year) ¥ 0.5
Abbreviations: ED, emergency department; NH, nursing home.
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lished sources (Table 2). Other reasons cited for
medication-related hospitalizations and emergency
department visits include idiosyncratic adverse drug
reactions, including undocumented allergies, and
inappropriate self-medication [25,29].
Emergency department visits. Published sources
were used to estimate the percent of emergency
department (ED) visits per year that are medication-
related. This estimate was then used to calculate the
number of ED visits per year that occur in the eld-
erly as a result of adverse events (Table 1).
The base case percentage of ED visits (1.9%) is
the median of several published sources (Table 2)
[1,2,24,29]. Studies were excluded if they deﬁned a
medication-related visit from using the following
ICD-9 codes: E930.0 to E947.9 [30]. These were
excluded because medication-related visits that are
identiﬁed only by the ICD-9 code used would not
include visits related to compliance, inappropriate
prescribing, or therapeutic failure and would signif-
icantly underreport the total number of visits per
year.
The percentage of medication-related ED visits
Table 2 Medical utilization and pharmaceutical care parameters
Percentage of hospitalizations resulting from medication-related morbidity and mortality
Schneitman-McIntier et al., 1996 [24] 0.57
Lakshmanan et al., 1986 [27] 4.20
Einarson, 1993 [26] 5.10
Ernst and Grizzle, 2001 [2] 28
Col et al., 1990 [25] 28.20
Median 5.10
Percentage of medication-related hospitalizations resulting from noncompliance
Einarson, 1993 [26] 22.7
Col et al., 1990 [25] 40.4
Median 31.6
Percentage of medication-related hospitalizations resulting from inappropriate prescribing
Lakshmanan et al., 1986 [27] 48.6
Emergency department visits as a result of medication-related morbidity and mortality
Schneitman-McIntier and Farnen et al., 1996 [24] 0.56
Ernst and Grizzle, 2001 [2] 1.86
Prince et al., 1992 [29] 1.9
Dennehy et al., 1996 [1] 3.9
Median 1.9
Percentage of medication-related emergency room visits that are due to noncompliance
Dennehy et al., 1996 [1] 32.0
Prince et al., 1992 [29] 43.9
Median 38.0
Percentage of medication-related emergency room visits that are due to inappropriate prescribing
Dennehy et al., 1996 [1] 58.0
Increase in compliance as a result of pharmaceutical care (%)
Faulkner et al., 2000 [39] 24
Faulkner et al., 2000 [39] 25
Faulkner et al., 2000 [39] 27
McKenney et al., 1978 [40] 28
Bond and Monson, 1984 [41] 52
Bond and Monson, 1984 [41] 55
Median 28
Decrease in inappropriate prescribing as a result of pharmaceutical care (%)
Dobie and Rascati, 1994 [52] 4.0
Christensen et al., 2000 [51] 8.9
Rupp, 1992 [54] 11.8
Hanlon et al., 1996 [56] 19
Hanlon et al., 1996 [56] 23
Rupp, 1998 [53] 30
Tamai et al., 1987 [55] 40
Morrill and Barreuther, 1988 [57] 121.6
Median 21.0
Percentage of medications discontinued as a result of pharmaceutical care
Hanlon et al., 1996 [56] 9
Tamai et al., 1987 [55] 22
Borgsdorf et al., 1994 [59] 39.9
Median 22
Decrease in mortality as a result of pharmaceutical care (%)
Yuan et al., 2003 [63] 7.9
Decrease in hospitalizations as a result of pharmaceutical care (%)
Yuan et al., 2003 [63] 2.8
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that were a result of inappropriate prescribing
(58.0%) and compliance (38.0%) were based on
published literature (Table 2).
Ofﬁce visits. The number of medication-related
ofﬁce visits per year incurred by the elderly was cal-
culated by multiplying the percentage of ofﬁce visits
that were elderly by the estimated number of med-
ication-related ofﬁce visits per year (Tables 1 and 3).
This was then multiplied by the average cost of an
ofﬁce visit in 2000 to determine the total cost of
medication-related ofﬁce visits for the elderly per
year.
Nursing home admissions. It has been well
established that polypharmacy and inappropriate
medication use in the elderly leads to impaired cog-
nition and falls [31–36]. Because these events are
risk factors for nursing home admission [37,38], it
is reasonable to assume that many nursing home
admissions are a result of improper medication use.
We estimate that 25% of nursing home (NH)
admissions are medication-related. This estimate
was used to calculate the number of NH admissions
that occur in the elderly per year because of adverse
events (Table 3). Since it is most likely that many of
these residents would have been admitted at some
point for other comorbid reasons, our model con-
servatively assumes that medication-related events
cause an admission to occur 6 months prematurely,
but does not increase the total number of nursing
home admissions.
Beneﬁts of Pharmaceutical Care
Compliance. Pharmacists’ impact on compliance
was estimated as the median of several published
sources (increase of 28%) in the base case (Table 2)
[39–41]. Studies were excluded if the measure used
to evaluate compliance, such as a compliance score,
could not be combined with the measure used in the
source data, which was the percentage of patients
compliant with medications [42–44]. Studies were
also excluded if they reported unrealistic baseline or
control compliance, which was compliance greater
than 85% with no intervention [45,46].
Inappropriate prescribing. It was assumed the
median rate of inappropriate prescribing in the eld-
erly population is 9%. This is the average of rates
reported in several studies of retrospective reviews
of inappropriate medication use in the elderly [47–
50]. Studies reporting the number of errors found
by pharmacists in a community setting were used to
calculate the percentage of errors identiﬁed from the
number of errors expected for the quantity of pre-
scriptions ﬁlled [51–54].
Pharmacists’ impact on inappropriate prescrib-
ing was estimated as the median of several pub-
lished sources (decrease of 21%) in the base case
[51–57]. Studies were excluded from the analysis if
they included only errors of dosage or incomplete
prescriptions [58], were not representative owing to
the subjects being referred patients [59], reported
the number of interventions per patient versus per
number of prescriptions [60], reported unrealistic
results (0.6 errors per 100 prescriptions) [61], or did
not report the corrected errors as a percentage of
total prescriptions screened [62].
Pharmacist impact on hospitalizations and
ofﬁce visits. Pharmaceutical care has been found
to decrease overall hospitalizations by 2.8%
(Table 2) [63]. This corresponds to a relative
decrease of 55% of medication-related hospitaliza-
tions. In the base case, the estimated cost savings
using this source ($3.8 billion per year) was aver-
aged with the estimated cost savings from the reduc-
tion in hospitalizations as a result of increased
compliance ($606 million per year) and decreased
inappropriate prescribing ($711 million per year).
The estimate of medication-related ofﬁce visits
was not divided into those that were related to
inappropriate prescribing and those related to non-
compliance. For this reason, the impact of pharma-
ceutical care on ofﬁce visits was assumed to be the
mean of the impact on compliance and inappropri-
ate prescribing. Since these are factors related to
emergency department visits and hospitalizations, it
is reasonable to assume that they are also related to
ofﬁce visits and that any impact on compliance and
inappropriate prescribing would lead to a decrease
in medication-related ofﬁce visits as well.
Costs of Providing Pharmaceutical Care
It was assumed that 5 hours of pharmaceutical care
would be provided to each patient in the ﬁrst year
of implementation and then 2.5 hours per year in
each subsequent year. The majority of intervention
time would occur during the beginning of the year
with follow-up occurring as needed (e.g., after a
change in therapy or assessment of noncompliance)
throughout the rest of the year. The additional time
would be required in the initial year to review a
patient’s medication history and provide more
intensive counseling on the importance of compli-
ance, etc. In the following years, the pharmacists
would then monitor changes in the patient’s medi-
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cation regimen and recounsel the patient regarding
compliance when deemed necessary (e.g., if reﬁll
patterns indicate the patient is exhibiting noncom-
pliance). Christensen et al. [51] reported an average
of 7.5 minutes per prescription was required for
each intervention initiated. Using this estimate,
patients could have ﬁve prescriptions ﬁlled per
month and still require less than 5 hours of phar-
maceutical care in the ﬁrst year.
The cost equations are shown in Table 1. To be
conservative, $40 was chosen as the base case phar-
macist hourly wage. The median wage for a phar-
macist in the United States in 1999 was $32.16. The
19th percentile was $42.68 (Bureau of Labor Sta-
tistics). Including fringe beneﬁts of 27% (http://
www.bls.gov/ncs/home.htm, accessed September 22,
2001); this amounts to $51 per hour (Table 3).
Decreased Cost of Prescriptions as a Result of 
Discontinuation of Medications
Pharmacists’ impact on the discontinuation of
duplicate, nonindicated, or contraindicated medi-
cations were taken as the median of several pub-
lished sources (Table 2) [55,56,59]. Total drug
expenditures for the elderly were calculated by
multiplying the total expenditure on prescription
drugs in the United States (Table 3) by the percent-
age of medication expenditures that are incurred
by the elderly [64]. The savings per year from dis-
continued medications was calculated by multiply-
ing pharmacists’ impact on discontinuation by the
total pharmacy expenditures of the elderly per
year.
Cost of Additional Prescription Fills as a Result of 
Increased Compliance
Assuming that pharmaceutical care resulting in a
28% increase in compliance, the cost of the addi-
tional prescription ﬁlls was calculated by multi-
plying this percentage by the total pharmacy
expenditures for the elderly per year (see
“Decreased Cost of Prescriptions as a Result of Dis-
containment of Medications”).
Calculation of Cost of Pharmaceutical Care
Savings owing to decreased hospitalizations and
emergency department visits were calculated by
multiplying pharmacists’ impact on compliance and
inappropriate prescribing by the percentage of hos-
pitalizations and emergency department visits
resulting from these two factors. The overall cost of
pharmaceutical care per year was determined by
subtracting the savings from the reduction in med-
ication costs, hospitalizations, emergency depart-
ment, ofﬁce visits, and nursing home admissions
from the cost of providing additional medications
and pharmaceutical care. All costs were measured
in year 2000 US dollars. The cost of providing phar-
maceutical care over the course of a lifetime was
calculated using a Markov probability-based back-
ward induction algorithm (Table 1). Total costs for
the cohort of elderly individuals in the United States
were estimated.
Beneﬁts
Life-years saved. The number of life-years saved
was calculated using a Markov probability-based
backward induction algorithm (Table 1). Standard
annual mortality probabilities at ages 65 to 100
were obtained from National Center for Health Sta-
tistics (NCHS) Web site [68].
The base case probability of dying for the general
population from medication-related problem
(9.3%) was determined by using the projected
number of 218,000 medication-related deaths in the
total population per year [2] divided by total
number of deaths (2,337,356) in the United States
per year [69]. This probability was then adjusted to
Table 3  Base case parameters
Parameter Value
Total number of hospitalizations in the United
States per year
34,180,563 [63]
Percentage of hospitalized patients who are
elderly
36 [63]
Average cost of a hospitalization $11,112.37*
Total number of ED visits made by the elderly
per year
15,482,000 [66]
Average cost of an ED visit $516.81†
Total number of medication-related ofﬁce visits
per year
126,846,567 [2]
Percentage of ofﬁce visits by patients who are
elderly
23.8 [65]
Cost of an ofﬁce visit $109 [2]
Total number of NH admissions per year 1,800,000 [67]
Percentage of NH residents who are age 65 and
older
91 [64]
Percentage of NH admissions that are
medication-related
25
Average monthly charge for NH stay $3891 [65]
Number of elderly people in the United States 34,910,122‡
Total expenditures on prescriptions per year $121 billion§
Hourly compensation of a pharmacist $51
Number of medication-related deaths in the
United States per year
218,000 [2]
*Healthcare Cost and Utilization Project 1997: http://hcup.ahrq.gov/HCUP-
net.asp, accessed May 27, 2001.
†National Medical Expenditures Survey 1987 (2000 aged data).
‡Resident  population  estimates  of  the  United  States  by  age  and  sex:
http://www.census.gov, accessed July 27, 2001.
§Personal Health Care Expenditures, by Type of Expenditure for Calendar Years 1994–
2001, Health Care Financing Administration: http://www.hcfa.gov/stats/nhe-
oact/tables/t9.htm, accessed May 10, 2002.
Abbreviations: ED, emergency department; NH, nursing home.
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the elderly population by multiplying the general
population’s probability of dying from a medica-
tion-related problem by the probability of dying at
each year of age between 65 and 100 (as reported in
the NCHS life-tables). This resulted in an estimated
168,000 medication-related deaths in the elderly
per year. Pharmaceutical care has been found to
decrease overall mortality by 7.9% [63]. This trans-
lates into an 85% risk reduction in medication-
related deaths per year.
Since inappropriate prescribing and lack of com-
pliance are factors in increased health-care utiliza-
tion, it is reasonable to assume that they would also
be factors in medication-related deaths. An inter-
vention that would impact health-care utilization
would most likely also subsequently affect the
number of medication-related deaths in a propor-
tional manner. Since the study conducted by Yuan et
al. [63] is conducted in a managed care population,
to be conservative, we assumed that pharmacists’
impact on mortality was the average of the impact
on compliance, inappropriate prescribing, and the
reduction in medication-related deaths per year
(Fig. 1).
Results
Base Case
Using the “best choice” parameter values described
above (Tables 2 and 3), a comprehensive pharma-
ceutical care program applied to the entire Medi-
care elderly population (after accounting for savings
seen in decreased medication use, hospital admis-
sions, emergency department and ofﬁce visits, and
nursing home admissions) would have a net cost of
$16.7 billion annually. The total number of life-
years saved was projected to be 7.9 million for a
cost-effectiveness ratio of $2100 per life-year saved
(Table 4).
Sensitivity Analyses
One-way sensitivity analyses were performed on
selected variables (Table 5). Ranges were selected
based on the high and low values from studies pre-
viously identiﬁed. The lower bound for annual
deaths that are medication-related was based on
Lazarou et al. [10]. Since this estimate is based on a
hospitalized population rather than a general pop-
ulation it is most likely an underestimate of the total
number of medication-related deaths [10].
The one-way sensitivity analyses are shown in
Fig. 2. The variable that elicits the greatest impact
on the model is the discontinuation of medications
as a result of pharmaceutical care. Similarly, the
additional costs resulting from increased compli-
ance also exhibit great impact on the model. These
two parameters dominate the overall cost of phar-
maceutical care. The percentage of nursing home
admissions delayed for 6 months because of phar-
maceutical care has relatively little impact on the
model and excluding this beneﬁt altogether results
in a cost-effectiveness ratio of $4586 per life-year
saved.
Fifty-thousand dollars per life-year saved is often
cited as an upper threshold value for interventions
that should be adopted [70,71]. The base case
assumes that pharmacists would spend 5 hours per
Figure 1 Probability of dying at each age from medication-related
causes with and without pharmaceutical care.
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Table 4  Summary of base case results
Outcome Cost savings
Direct cost of pharmaceutical care $47.9 billion
Cost of increased compliance $109.2 billion
Savings from hospitalizations, ED and ofﬁce visits,
and NH admissions
$53.3 billion
Savings from discontinued medications $87.2 billion
Net cost of pharmaceutical care $19.2 billion
Number of life-years saved 7.9 million
Cost per life-year saved $2100
Abbreviations: ED, emergency department; NH, nursing home.
Table 5  Variables and ranges used in one-way sensitivity
analyses
Variable Range
1. Number of medication-related deaths
per year
106,000–218,000
2. Pharmacist impact (%) on compliance 24–55
3. Pharmacist impact (%) on inappropriate
prescribing
3.9–40
4. Pharmacist impact (%) on discontinuing
edications
 9–39.9
5. Average number of hours of
pharmaceutical care required in the
ﬁrst year (with 50% of the amount
provided in subsequent years) 
 3–7.5
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year the ﬁrst year and then 2.5 hours per year there-
after on the pharmaceutical care interventions.
Holding other factors constant, the pharmacist
could provide as much as 44 hours of pharmaceu-
tical care in the ﬁrst year and 22 hours in each
subsequent year and still fall below the cost-
effectiveness threshold of $50,000 per life-year
saved.
Inserting the most conservative value of each
range for each variable (Table 5) the intervention
is still below the cost-effectiveness threshold at
$28,934 per life-year saved. Utilizing the most con-
servative values for all variables, the intervention
surpasses the $50,000 cost-effectiveness threshold
when the number of annual medication error-related
deaths without pharmaceutical care is assumed
lower than 60,000 ($51,249 per life-year saved).
Discussion
This analysis shows the cost-effectiveness of utiliz-
ing pharmaceutical care for the Medicare-eligible
elderly population of the United States. The phar-
maceutical care interventions cited in this study
used various methods to provide medication man-
agement services including patient counseling at the
time of dispensing [40,46], medication review at
the time of dispensing [52–56], telephone contact
[39], and chart review and counseling at a clinic
[41,44]. Although this study does not specify a par-
ticular method of delivery, any medication moni-
toring system for ambulatory patients that can
deliver the base case 28% reduction in noncompli-
ance and 21% reduction in inappropriate prescrip-
tion errors assumed for a pharmacist-delivered
intervention at a cost of $2244 in the ﬁrst year and
$1122 per year thereafter would be cost-effective.
These interventions may include any combination
of the following: monitoring of patient compliance
via reﬁll patterns, counseling of patients on the
importance of compliance, and review of patient
medication histories for therapy duplication, drug–
drug interactions, drug–disease interactions, medi-
cations that are no longer necessary, or inappropri-
ate medications.
Pharmacists are already in shortage, and excess
demand for pharmacy manpower is projected for
the foreseeable future [72]. However, our cost-effec-
tiveness model is not restricted to pharmacist-only
interventions. Any medication therapy management
services provided by a qualiﬁed health-care profes-
sional that meet the base case assumptions above
would be cost-effective. This suggests tremendous
potential for a variety of programs that can enhance
medication monitoring.
Unfortunately, because of the lack of data
describing the change in patient utility as a result of
pharmaceutical care, we were unable to include cost
per quality-adjusted life-year measures in this anal-
ysis. It may be hypothesized that patients who
receive pharmaceutical care would experience bet-
ter management of chronic disease states and sub-
sequently enjoy a higher quality of life. However, in
some asymptomatic disease states, such as hyper-
tension, some patients may actually experience a
decreased quality of life from an increase in com-
pliance and subsequent increase in undesirable side
effects from the medications. An analysis including
change in quality of life would need to be performed
across all speciﬁc disease states.
Limitations of this analysis result from the lack
of precise estimates for many of the parameters. The
estimate of medication-related deaths is based on a
decision model analysis that utilized an expert panel
to obtain probabilities for the decision tree [2],
ICD-9 codes for medication-related deaths, or esti-
mation based on inpatient data [10]. Additionally,
the varying deﬁnitions of “medication-related,”
“adverse drug reaction,” and “medication error” in
the literature led to nonstandard reporting methods
in many of the studies used. Similarly, the practice
sites represented for the pharmacist interventions
varied in both nature and type. Although most were
community pharmacies, some were outpatient serv-
ices connected with a medical center.
Because of limited elderly-speciﬁc data, the
model includes studies that were conducted in the
general population. It may be argued that the eld-
Figure 2 One-way sensitivity analyses of model parameters. *The
hours of pharmaceutical care provided in the ﬁrst year (with 50%
provided in the subsequent years). †The percentage of medications
discontinued as a result of pharmaceutical care. ‡The percentage of
medication errors related to prescriptions ﬁxed as a result of phar-
maceutical care. §The percentage increase in compliance rate as a
result of pharmaceutical care. ||The number of medication-related
deaths in the total population per year.
(10,000) (5,000) 0 5,000 10,000 15,000 
One-Way Sensitivity Analysis 
Cost Per Life-Year Saved 
II of Med-related Deaths 
§ Increase in Compliance 
‡ Errors Fixed 
† % of Meds DC'd 
* Hours of Pharm Care 
216,000-106,000 
24%-55% 
40%-3.9% 
39.9%-9.0% 
3 - 7.5 
Base Case:  
$2,100 per life-year 
Medicare Drug Monitoring Cost-Effectiveness 433
erly are more susceptible to medication-related
morbidity and mortality. In this case, the potential
savings from pharmaceutical care would be
increased. This model would then be a conservative
projection of the cost-effectiveness of pharmaceuti-
cal care in the elderly.
Despite these limitations, the model presented
produces robust results. Aside from the number of
deaths that are medication-related, no individual
variations in parameters raised the cost-effectiveness
ratio above $14,000 per life-year saved. Even at
this level, pharmaceutical care is an extremely cost-
effective intervention. Using the most conservative
estimates for all parameters, the employment of
pharmaceutical care in the elderly population was
still well below the common threshold value of
$50,000 per life-year saved. Because of the variety of
practice sites represented—with little change in
overall outcome—it can also be suggested that phar-
maceutical care would be cost-effective across many
practice settings.
Further work should be performed to determine
the additional beneﬁts received from pharmacists’
monitoring of patients’ medication regimens. This
study did not address the cost-effectiveness or
potential cost savings of pharmacists’ monitoring of
medication therapy and did not include any costs or
beneﬁts associated with these additional services.
This will most likely need to be done on a disease-
by-disease basis to determine the medical cost and
life-year savings achieved by monitoring blood pres-
sure, lipid levels, blood glucose levels, and other sec-
ondary indicators of effectiveness to maximize the
beneﬁts received from medication therapy.
L.R.E. was in the USC Department of Pharmaceutical
Economics and Policy the time this study was conducted.
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